Physician profile
James Lin
NPI 1932122579
$2,701.57
in general payments reported to CMS, 2019-2025
26 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $377 · 2020: $139 · 2021: $142 · 2022: $361 · 2023: $677 · 2024: $507 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $738.51 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Glaxosmithkline, LLC. | $251.02 | 2019-2023 | Arexvy, Shingrix |
| Lilly USA, LLC | $187.94 | 2019-2024 | Mounjaro, Zepbound |
| Heartflow, INC. | $168.29 | 2025 | |
| Sanofi-Aventis U.S. LLC | $140.63 | 2019-2022 | |
| Allergan, INC. | $128.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2024 | Jardiance |
| Erbe USA INC | $111.89 | 2025 | Vio3 |
| Takeda Pharmaceuticals U.S.A., INC. | $110.26 | 2020-2023 | Takhzyro |
| Bayer Healthcare Pharmaceuticals INC. | $103.22 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $87.00 | 2023 | Givlaari |
| Merck Sharp & Dohme LLC | $73.65 | 2019-2025 | Gardasil 9, Rotateq, Vaxneuvance |
| Sanofi Pasteur INC. | $68.62 | 2020-2025 | |
| Novo Nordisk INC | $61.50 | 2023 | Rybelsus, Ozempic, Tresiba |
| Fresenius Kabi USA, LLC | $48.59 | 2023-2024 | Idacio |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $43.64 | 2019 | |
| Genzyme Corporation | $39.56 | 2021-2022 | |
| Exact Sciences Corporation | $39.10 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $32.91 | 2020-2021 | |
| Sumitomo Pharma America, INC. | $26.95 | 2023 | Gemtesa |
| Radius Health, INC. | $24.03 | 2023 | Tymlos |
| Pfizer INC. | $20.93 | 2023 | |
| Amarin Pharma, INC. | $20.30 | 2021 | |
| Seqirus USA INC | $19.22 | 2024 | Fluad, Flucelvax |
| Amgen INC. | $18.05 | 2025 | Evenity |
| Abbvie INC. | $12.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.